About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > Assistance Available for Individuals Switching to Glatopa™

Assistance Available for Individuals Switching to Glatopa™


Sandoz, a Novartis company, recently launched Glatopa™ (glatiramer acetate injection) for the treatment of the relapsing-form of multiple sclerosis. Some people with MS are being switched to Glatopa, which is an FDA-approved generic substitutable for Copaxone ® 20 mg/mL, by their doctor, pharmacy, or managed care organization. However, some individuals who have switched have not received information about available support programs.

According to a statement from Sandoz, “We believe that some patients may have received inaccurate information regarding the service offering we provide to Glatopa patients. It is important for patients to fully understand, and quickly receive access to the services and support they need.”

A patient support program is available to provide assistance to individuals who have been switched to Glatopa. This assistance, called GlatopaCare includes several important services, including training and support for the injection device – which may differ from that used with their previous medication – and co-pay assistance, including a $0 copay option for eligible persons.

To learn more about the support available or to apply for this assistance, visit www.glatopa.com/register or call 855-GLATOPA (852-8672).

  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved